An altered peptide ligand of type II collagen suppresses autoimmune arthritis

Critical Reviews in Immunology

Volumn 27, Issue 4, 2007, Pages 345-356

  Myers, Linda K ^a,c   Tang, Bo ^a,b   Rosioniec, Edward F ^a,b   Stuart, John M ^a,b   Kang, Andrew H ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Division of Rheumatology   (United States)

Author keywords

Arthritis; Autoimmunity; Collagen; Peptides; T cells

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LIGAND; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOTHERAPY; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL LINE; COLLAGEN TYPE II; CYTOKINES; IMMUNOTHERAPY; LIGANDS; MEMBRANE PROTEINS; MICE; MICE, INBRED DBA; PEPTIDE FRAGMENTS; PHOSPHORYLATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 38049063424     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Carlsen S, Hansson AS, Olsson H, Heinegard D, Holmdahl R. Cartilage oligomeric da:matrix protein (COMP)-induced arthritis in rats. Clin Exp Immunol. 1998;114:477-84.
2. He X, Kang AH, Stuart JM. Anti-human type II collagen CD19+ B cells are present in patients with rheumatoid arthritis and healthy individuals. J Rheumatol. 2001;28:2168-75.
3. Jasin H. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1985;28:241-8.
4. Kim WU, Yoo WH, Park W, Kang YM, Kim SI, Park JH, Lee SS, Joo YS, Min JK, Hong YS, Lee SH, Park SH, Cho CS, Kim HY. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol. 2000;27:575-81.
5. Nissim A, Winyard PG, Corrigall V, Fatah R, Perrett D, Panayi G, Chernajovsky Y. Generation of neoantigenic epitopes after posttranslational modification of type II collagen by factors present within the inflamed joint. Arthritis Rheum. 2005;52:3829-38.
6. Ronnelid J, Lysholm J, Engstrom-Laurent A, Klareskog L, Heyman B. Local anti-type II collagen antibody production in rheumatoid arthritis synovial fluid: Evidence for an HLA-DR4-restricted IgG response. Arthritis Rheum. 1994;37:1023-29.
7. Watson W, Cremer M, Wooley P, Townes A. Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis. Arthritis Rheum. 1986;29:1316-21.
8. Watson WC, Tooms RE, Carnesale PG, Dutkowski JP. A case of germinal center formation by CD45RO T and CD20 B lymphocytes in rheumatoid arthritis subchondral bone: proposal for a two compartment model of immune-mediated disease with implications for immunotherapeutic strategies. Clin Immunol Immunopathol. 1994;73:27-37.
9. Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M,.Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J Exp Med. 1997;185:1113-22.
10. Rosloniec EF, Brand DD, Myers LK, Esaki Y, Whittington KB, Zaller DM, Woods A, Stuart JM, Kang AH. Induction of autoimmune arthritis in HLADR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol. 1998;160:2573-8.
11. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000;6:1167-75.
12. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med. 2001;79:552-65.
13. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L, Rae-Grant A, Castaldo J, Eckert N, Guarnaccia JB, Mills P, Johnson G, Calabresi PA, Pozzilli C, Bastianello S, Giugni E, Witjas T, Cozzone P, Pelletier J, Pohlau D, Przuntek H, Hoffmann V, Bever C Jr, Katz E, Clanet M, Berry I, Brassat D, Brunet I, Edan G, Duquette P, Radue EW, Schott D, Lienert C, Taksaoui A, Rodegher M, Filippi M, Evans A, Bourgouin P, Zijdenbos A, Salem S, Ling N, Alleva D, Johnson E, Gaur A, Crowe P, Liu XJ. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med. 2000;6:1176-82.
14. Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin Immunol. 2002;104:105-14.
15. Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther. 2005;7:93-9.
16. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D, Lanza P, Berry C, Massa M, Billetta R, Albani S. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2004;101:4228-33.
17. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol. 1998;161:3589-95.
18. Myers L, Rosloniec E, Seyer J, Stuart J, Kang A. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J Immunol. 1993;150:4652-8.
19. Stuart JM, Cremer MA, Kang AH, Townes AS. Collagen-induced arthritis in rats. Evaluation of early immunologic events. Arthritis Rheum. 1979;22:1344-51.
20. Kanomi H, Seyer JM, Ninomiya Y, Olsen BR. Peptide-specific antibodies identify the α2 chain as the proteoglycan subunit of type IX collagen. J Biol Chem. 1986;261:6742-6.
21. Rosloniec EF, Kang AH, Myers LK, Cremer MA. Collagen-induced arthritis. In: Coico R, Shevach E, editors. Current protocols in immunology. New York: Wiley; 1997. p. 11-24.
22. Gullick W. Production of antisera to synthetic peptides. Totowa (NJ): Humana Press; 1988.
23. Tang B, Myers LK, Rosloniec EF, Whittington KB, Stuart JM, Kang AH. Characterization of signal transduction through the TCR-zeta chain following T cell stimulation with analogue peptides of type II collagen 260-267. J Immunol. 1998;160:3135-42.
24. Tang B, Mano H, Yi T, Ihle J. Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding. Mol Cell Biol. 1994;14:8432-7.
25. q mice. J Immunol. 1994;152:3088-97.
26. Smilek DE, Wraith DC, Hodgkinson S, Dwivedy S, Steinman L, McDevitt HO. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 1991;88:9633-7.
27. Wauben MH, Hoedemaekers AC, Graus YM, Wagenaar JP, van Eden W, de Baets MH. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response. Eur J Immunol. 1996;26:2866-75.
28. Rosloniec EF, Whittington KB, Brand DD, Myers LK, Stuart JM. Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis. Cell Immunol. 1996;172:21-8.
29. Dittel B, Sant Angelo D, Janeway C. Peptide antagonists inhibit proliferation and the production of IL-4 and/or IFN-? in T helper 1, T helper 2, and T helper 0 clones bearing the same TCR. J Immunol. 1997;158:4065-73.
30. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med. 1993;177:1047-60.
31. Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegard D, van den Berg WB. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1999;1:81-91.
32. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, RobbinsPD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol. 2001;166:3499-505.
33. Nishibori T, Tanabe Y, Su L, David M. Impaired development of CD4+ CD25+ regulatory T cells in the absence of STAT1: increased susceptibility to autoimmune disease. J Exp Med. 2004;199:25-34.
34. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20. J Immunol. 2001;167:3545-9.
35. Myers LK, Tang B, Stuart JM, Kang AH. The role of IL-4 in regulation of murine collagen-induced arthritis. Clin Immunol. 2002;102:185-91.
36. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991;252:1308-10.
37. Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta FCA, Colón SM, Grey HM, Sette A. Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol. 1993;150:1-7.
38. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunology Today. 1993;14:602-9.
39. Evavold BD, Sloan-Lancaster J, Hsu BL, Allen PM. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analog peptides. J Immunol. 1993;150:3131-40.
40. Kersh GJ, Allen PM. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med. 1996 184:1259-68.
41. Pfeiffer C, Stein J, Southwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med. 1995;181:1569-74.
42. Tao X, Grant C, Constant S, Bottomly K. Induction of IL-4-producing CD4+ T cells by antigenic peptides altered for TCR binding. J Immunol. 1997;158:4237-44.
43. Krishnan S, Farber DL, Tsokos GC. T cell rewiring in differentiation and disease. J Immunol. 2003;171:3325-31.
44. Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol. 2004;172:7821-31.
45. Letourneur F, Klausner RD. Activation of T cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon. Science. 1992; 255:79-82.
46. Taylor N, Steinberg M, Oumeya A, Swainson L, Merida P, Noraz N, Di Bartolo V, Pelletier L. T cell receptor-induced phosphorylation of the {zeta} chain is efficiently promoted by ZAP-70 but not Syk. Blood. 2004;104:760-7.
47. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL, Doherty P, Ihle JN. Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. Immunity. 2004;20:37-46.
48. Myers LK, Higgins GC, Finkel TH, Reed AM, Thompson JW, Walton RC, Hendrickson J, Kerr NC, Pandya-Lipman RK, Shlopov BV, Stastny P, Postlethwaite AE, Kang AH. Juvenile arthritis and autoimmunity to type II collagen. Arthritis Rheum. 2001;44:1775-81.
49. Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum. 1996;39:623-8.
50. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med. 2000;6:1176-82.
51. Hobeika AC, Morse MA, Osada T, Ghanayem M, Niedzwiecki D, Barrier R, Lyerly HK, Clay TM. Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother. 2005;28:63-72.
52. Sarvetnick N. Mechanisms of cytokine-mediated localized immunoprotection. J Exp Med. 1996;184:1597-600.